Background
==========

At present, the only treatment for coeliac disease is a lifelong gluten-free diet, i.e. exclusion of wheat-, rye- and barley-containing cereals and food products. Upon removal of gluten from the diet clinical symptoms are usually rapidly alleviated, while recovery of the duodenal mucosa may take several months or even years \[[@B1]\]. The treatment may also prevent many coeliac disease-associated complications such as intestinal malignancies \[[@B2]\]. Notwithstanding these benefits, the stigma of a chronic disorder and the need for major dietary restrictions increases the self-perceived burden of illness and may impair patients' quality of life \[[@B3],[@B4]\]. The symptoms may also remain despite a long-term and strict diet \[[@B5],[@B6]\]. As a result, in some studies even well-treated coeliac patients have failed to attain well-being similar to that of the population in general \[[@B7],[@B8]\], albeit that there are also contradictory results \[[@B9],[@B10]\]. To improve the situation, knowledge of the factors underlying these persistent health concerns in coeliac patients is required. Thus far, only a limited number of studies have investigated this issue \[[@B11]\]; data are scant, particularly in screen-detected patients and in subjects with extraintestinal presentation \[[@B9],[@B12]\].

The aim of this large nationwide study was to find predictors of persistent gastrointestinal symptoms and reduced health-related quality of life in long-term treated adult coeliac patients. Particular attention was devoted to aspects such as duration and severity of symptoms before diagnosis and presence of coeliac disease-associated and other co-morbidities.

Methods
=======

Study design and participants
-----------------------------

The trial was conducted at the Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital. Adult volunteers were recruited by a nationwide search using newspaper advertisements and via national and local coeliac disease societies. The study cohort comprised a total of 596 adults (age \> 18 years) with biopsy-proven coeliac disease. All coeliac diagnoses and other relevant medical data (see below) were confirmed from the patients' medical records. Subjects who had been on a gluten-free diet less than one year, had biopsy-proven refractory coeliac disease, or whose coeliac disease diagnosis could not be verified were excluded from the study.

All eligible subjects filled self-administered, validated and structured gastrointestinal symptom and corresponding health-related quality of life questionnaires. Next, to reveal factors associated with persistent symptoms and poor quality of life, the participants were interviewed by a physician or study nurse with expertise in coeliac disease. They were asked to report their demographic data and family history of coeliac disease, clinical presentation of the condition, time and place of diagnosis (primary, secondary or tertiary health care), dietary counseling and regular follow-up, adherence to the gluten-free diet, possible consumption of oats and duration of diet. Furthermore, the presence of coeliac disease-associated or other significant co-morbidities such as autoimmune thyroidal disease or type 1 diabetes, was inquired after.

Clinical presentation at diagnosis was further categorized into gastrointestinal (any kind of gastrointestinal symptom or signs of malabsorption), extraintestinal (e.g. dermatitis herpetiformis, neurological symptoms or arthralgia) and screen-detected (subjects identified by screening in at-risk groups). Duration of symptoms was defined as first experienced symptom until diagnosis, and was divided into three subgroups as follows: no symptoms, symptoms 10 years or less and symptoms more than 10 years. Further, the self-perceived severity of the symptoms was asked and divided into three subgroups as follows: no symptoms, moderate symptoms and severe symptoms.

Altogether 110 healthy subjects (81% females, median age 49 (range 24--87) years) having no first-degree relatives with coeliac disease were used as a non-coeliac control group. The controls were recruited from the close neighborhood and among friends of the coeliac patients.

All participants gave written informed consent. The study protocol was approved by the Ethical Committee of Tampere University Hospital.

Health-related quality of life and gastrointestinal symptoms
------------------------------------------------------------

The current self-perceived gastrointestinal symptoms and health-related quality of life of the participants were evaluated by structured and well-validated questionnaires widely applied in coeliac disease research \[[@B7],[@B12]-[@B15]\]. The Gastrointestinal Symptom Rating Scale (GSRS) \[[@B16],[@B17]\] was used to evaluate gastrointestinal symptoms. The questionnaire comprises 15 separate items covering five different sub-dimensions: diarrhoea, indigestion, constipation, abdominal pain and reflux. The scoring is based on a 7-grade Likert scale in which 1 point indicates no symptoms and 7 points the most severe gastrointestinal symptoms. Values for each sub-dimension score are calculated as a mean of the relevant items. The total GSRS score is calculated as a mean value of all 15 items and may thus also gain values between 1 to 7 points. Patients with a score higher than 1 standard deviation (SD, 0.66 points) compared to the control mean were considered to have increased gastrointestinal symptoms \[[@B18]-[@B20]\]. The threshold score for increased symptoms was therefore 2.55 points.

The Psychological General Well-Being (PGWB) questionnaire \[[@B12],[@B13],[@B15],[@B21]\] was used to measure health-related quality of life. This survey consists of 22 separate items covering six different sub-dimensions: anxiety, depression, well-being, self-control, general health and vitality. The scoring is based on a 6-grade Likert scale in which higher scores indicate better quality of life. The value of the total PGWB score may range from a minimum of 22 to maximum 132. The sub-scores are calculated as a sum of the items in each sub-dimension in question. Subjects with a score less than 1 SD (12.1 points) compared to the control mean were considered to have reduced quality of life \[[@B18]-[@B20]\], so the threshold score was 93.1 points.

Adherence to the gluten-free diet
---------------------------------

The possible consumption of gluten-containing products was assessed by a combination of self-reported adherence and coeliac disease serology. Participants were rated strictly adherent if they reported being on a strict gluten-free diet in dietary interview and were found to be negative for serum endomysial (EmA) and transglutaminase 2 (TG2-ab) antibodies.

Serum IgA class EmA were measured by an indirect immunofluorescence method with human umbilical cord as substrate \[[@B22]\] and serum IgA class TG2-ab by enzyme-linked immunosorbent assay (QUANTA Lite h-tTG IgA, INOVA Diagnostics, San Diego, CA, USA). A dilution of 1: ≥5 for EmA was considered positive and positive samples were further diluted 1:50, 1:100, 1:200, 1:500, 1:1000, 1:2000 and 1:4000. In TG2-ab unit values ≥30 U/I were considered positive. In cases known to involve selective IgA deficiency, the corresponding IgG-class antibodies were applied.

Statistics
----------

Categorical data were described using percentages and quantitative data using medians with range. Binary logistic regression analysis was used to identify factors associated with reduced quality of life. Results are presented as odds ratios (OR) with 95% confidence intervals (CI). A p-value ≤ 0.05 was considered statistically significant. *T*-test was used to compare the GSRS and PGWB mean scores between coeliac patients and healthy controls.

If a patient failed to answer on one or two items in the PGWB or GSRS questionnaire, the missing answer was replaced by the mean value of the other scores for the same subject. If more than two answers were missing the questionnaire was disqualified. All statistical data were analyzed by the Predictive Analytic SoftWare for Windows version 19 (IBM Corporation, Armonk, NY, USA).

Results
=======

Clinical characteristics of the study cohort are shown in Table [1](#T1){ref-type="table"}. In total, 69% of the subjects were diagnosed on the basis of classical gastrointestinal presentation and 31% on the basis of extraintestinal symptoms or by screening in at-risk coeliac disease groups. Altogether 88% of the subjects were strictly adherent; none reported totally unrestricted gluten consumption and 82% used oats as a regular part of their diet. Lactose intolerance was present in 17%, food allergy in 5% and fructose intolerance in none of the participants. Further, 6% of the subjects had reflux disease, 4% gastritis, 2% diverticulosis and 2% cholelithiasis. The most common psychiatric disorder was depression, with a prevalence of 2% (78% of subjects with psychiatric diagnosis).

###### 

Demographic data and clinical characteristics of the 596 coeliac disease patients

  **Female, n (%)**                                       **452 (76)**
  ----------------------------------------------------- --------------
  Current age, median (range), years                       55 (19--92)
  Age at diagnosis, median (range), years                   44 (1--82)
  Site of diagnosis, n (%)                                            
    Primary care                                              149 (25)
    Secondary or tertiary care                                446 (75)
  Presenting symptom at time of diagnosis, n (%)                      
    Gastrointestinal ^1^                                      410 (69)
    Extraintestinal ^2^                                        95 (16)
    Screen-detected ^3^                                        91 (15)
  Coeliac disease in family, n (%)                            372 (62)
  Coeliac disease-associated disorders, n (%)                         
    Type 1 diabetes mellitus                                    14 (2)
    Thyroid disease                                           107 (18)
  Gluten-free diet, n (%)                                             
  Strict                                                      520 (88)
  Occasional gluten                                            76 (12)
  No diet                                                            0
  Consumption of oats, n (%)                                  487 (82)
  Duration of gluten-free diet, median (range), years       10 (1--53)

^1^Stomach pain, diarrhoea, constipation, heartburn, flatulence, swelling, anaemia, malabsorption.

^2^Dermatitis herpetiformis, tiredness, joint pains, neurologic symptoms, gynaecologic problems.

^3^Coeliac disease in relatives, presence of autoimmune disorder.

The mean total GSRS score was 2.1 (range 1.0- 4.8) in the study group and 1.9 (range 1.0- 4.2) in the controls. The score was higher than 1 SD compared to the control mean in 25% of the participants. There was no significant association between the persistent gastrointestinal symptoms and gender or current age, but patients diagnosed between the age of 25 and 60 years had more persistent symptoms than those diagnosed at younger or older age (Table [2](#T2){ref-type="table"}). Further, subjects who had suffered from moderate or severe symptoms at the time of the diagnosis or had had symptoms more than 10 years before it had more current gastrointestinal symptoms than initially asymptomatic patients. Patients diagnosed on extraintestinal symptoms had fewer current symptoms than those with gastrointestinal presentation (Table [2](#T2){ref-type="table"}). The presence of thyroid disease, non-coeliac food intolerance, other gastrointestinal disease and any coeliac disease-related co-morbidity also increased the risk of persistent symptoms. None of the other variables examined, including dietary non-adherence and consumption of oats, was associated with persistent symptoms. The GSRS mean total score was significantly higher in the study participants than in control subjects (p= 0.003).

###### 

**Factors associated with persistent gastrointestinal symptoms**\* **in treated coeliac disease patients**

  **Variable**                                                       **n**   **Symptoms, %**   **OR**   **95% CI**   **p-value**
  ---------------------------------------------- ------------------ ------- ----------------- -------- ------------ -------------
  Gender                                         Male                 144          22           1.00                       
                                                 Female               452          26           1.26    0.80-1.97       0.317
  Present age, years                             \< 25                12           20           1.00                       
                                                 25-60                380          24           1.25    0.26-6.01       0.778
                                                 \> 60                204          27           1.51    0.31-7.33       0.611
  Age at diagnosis, years                        \< 25                79           13           1.00                       
                                                 25-60                457          27           2.86    1.38-5.91       0.050
                                                 \> 60                60           20           1.99    0.77-5.10       0.154
  Symptoms at diagnosis                          Gastrointestinal     410          27           1.00                       
                                                 Extraintestinal      95           17           0.56    0.31-1.00       0.050
                                                 Screen-detected      91           24           0.88    0.52-1.49       0.636
  Duration of symptoms before diagnosis, years   No symptoms          37           11           1.00                       
                                                 ≤ 10                 350          22           2.33    0.80-6.77       0.121
                                                 \> 10                182          34           4.16    1.41-12.28      0.010
  Severity of symptoms at diagnosis              No symptoms          62           13           1.00                       
                                                 Moderate             457          25           2.27    1.05-4.91       0.037
                                                 Severe               77           31           3.06    1.26-7.41       0.013
  Site of diagnosis                              Hospital             446          25           1.00                       
                                                 Primary care         149          25           1.01    0.66-1.55       0.967
  Coeliac disease in family                      Yes                  372          24           1.00                       
                                                 No                   224          25           1.02    0.73-1.57       0.731
  Type 1 diabetes mellitus                       No                   582          25           1.00                       
                                                 Yes                  14           29           1.23    0.38-3.97       0.735
  Thyroid disease                                No                   489          22           1.00                       
                                                 Yes                  107          36           2.02    1.29-3.16       0.002
  Malignancy                                     No                   565          25           1.00                       
                                                 Yes                  31           26           1.04    0.47-2.43       0.884
  Psychiatric disease                            No                   578          24           1.00                       
                                                 Yes                  18           39           1.99    0.76-5.22       0.164
  Neurologic disease                             No                   520          24           1.00                       
                                                 Yes                  76           30           1.38    0.81-2.35       0.231
  Other food intolerance                         No                   470          22           1.00                       
                                                 Yes                  126          33           1.74    1.13-2.67       0.012
  Other gastrointestinal disease                 No                   388          22           1.00                       
                                                 Yes                  208          34           1.80    1.16-2.80       0.009
  Any coeliac disease-related co-morbidity       No                   72           14           1.00                       
                                                 Yes                  523          26           2.20    1.10-4.40       0.027
  Strict gluten-free diet                        Yes                  523          24           1.00                       
                                                 No                   73           27           1.17    0.68-2.04       0.570
  Consumption of oats                            No                   105          25           1.00                       
                                                 Yes                  487          23           0.87    0.54-1.41       0.568
  Duration of diet, years                        \> 10                270          27           1.00                       
                                                 5-10                 195          23           0.80    0.51-1.25       0.326
                                                 \<5                  131          25           0.92    0.57-1.42       0.730
  Professional dietary advice                    Yes                  484          24           1.00                       
                                                 No                   112          27           1.15    0.72-1.83       0.564
  Regular follow-up                              Yes                  166          25           1.00                       
                                                 No                   412          23           0.93    0.61-1.41       0.721

\*Defined as a score \>1 standard deviation from the mean Gastrointestinal Symptom Rating Scale total score of healthy controls; CI, confidence interval; OR, odds ratio defined by bivariate logistic regression.

The mean PGWB total score was 102.8 (range 29.0-132.0) in the study group and 105.3 (range 65.0-126.0) in the controls. Altogether 25% of the participants had the score lower than 1 SD compared to the control mean. Reduced health-related quality of life was seen in patients with manifest symptoms prior to diagnosis compared with asymptomatic subjects; the difference was evident in particular among those with symptoms for more than 10 years. Further, subjects with any psychiatric co-morbidity had reduced quality of life (Table [3](#T3){ref-type="table"}). A similar trend was observed in patients with neurological disease and gastrointestinal co-morbidity, but the results in question were not statistically significant (Table [3](#T3){ref-type="table"}). Of note, patients with persistent gastrointestinal symptoms were also more likely to have reduced quality of life (OR 4.66, CI 3.01-7.00, p \< 0.001). The coeliac patients had lower mean PGWB scores than healthy subjects (p = 0.05).

###### 

**Factors associated with persistently reduced quality of life**\* **in treated coeliac disease patients**

  **Variable**                                                       **n**   **Reduced, %**   **OR**   **95% CI**   **p-value**
  ---------------------------------------------- ------------------ ------- ---------------- -------- ------------ -------------
  Gender                                                Male          144          24          1.00                       
                                                       Female         452          25          1.07    0.69-1.67       0.777
  Present age, years                                   \< 25          12           10          1.00                       
                                                       25-60          380          26          3.21    0.40-25.66      0.272
                                                       \> 60          204          21          2.40    0.30-19.51      0.413
  Age at diagnosis, years                              \< 25          79           25          1.00                       
                                                       25-60          457          25          0.97    0.56-1.68       0.911
                                                       \> 60          60           22          0.82    0.37-1.81       0.617
  Symptoms at diagnosis                           Gastrointestinal    410          26          1.00                       
                                                  Extraintestinal     95           19          0.65    0.37-1.14       0.136
                                                  Screen-detected     91           22          0.79    0.46-1.36       0.389
  Duration of symptoms before diagnosis, years      No symptoms       37           8           1.00                       
                                                        ≤ 10          350          24          3.58    1.07-11.95      0.038
                                                       \> 10          182          28          4.41    1.30-15.01      0.017
  Severity of symptoms at diagnosis                 No symptoms       62           18          1.00                       
                                                      Moderate        457          26          1.61    0.81-3.20       0.170
                                                       Severe         77           22          1.31    0.56-3.06       0.527
  Site of diagnosis                                   Hospital        446          25          1.00                       
                                                    Primary care      149          24          0.97    0.63-1.50       0.902
  Coeliac disease in family                             Yes           372          25          1.00                       
                                                         No           224          24          0.97    0.66-1.42       0.864
  Type 1 diabetes mellitus                               No           582          25          1.00                       
                                                        Yes           14           21          0.84    0.23-3.04       0.785
  Thyroid disease                                        No           489          24          1.00                       
                                                        Yes           107          25          1.05    0.65-1.70       0.845
  Malignancy                                             No           565          25          1.00                       
                                                        Yes           31           13          0.44    0.15-1.28       0.132
  Psychiatric disease                                    No           578          23          1.00                       
                                                        Yes           18           67          6.63    2.44-17.99     \<0.001
  Neurologic disease                                     No           520          23          1.00                       
                                                        Yes           76           33          1.62    0.96-2.72       0.070
  Other food intolerance                                 No           470          24          1.00                       
                                                        Yes           126          28          1.24    0.80-1.94       0.335
  Other gastrointestinal disease                         No           388          23          1.00                       
                                                        Yes           208          32          1.56    1.00-2.45       0.052
  Any coeliac disease-related co-morbidity               No           72           26          1.00                       
                                                        Yes           523          24          0.89    0.51-1.56       0.691
  Strict gluten-free diet                               Yes           523          24          1.00                       
                                                         No           73           27          1.19    0.69-2.07       0.539
  Consumption of oats                                    No           105          22          1.00                       
                                                        Yes           487          25          1.19    0.72-1.98       0.497
  Duration of diet, years                              \> 10          270          23          1.00                       
                                                        5-10          195          23          0.96    0.61-1.52       0.875
                                                        \<5           131          29          1.35    0.84-2.18       0.221
  Professional dietary advice                           Yes           484          24          1.00                       
                                                         No           112          28          1.23    0.77-1.95       0.385
  Regular follow-up                                     Yes           166          24          1.00                       
                                                         No           412          24          1.00    0.65-1.52       0.986

\*Defined as a score \>1 standard deviation from the mean Psychological General Well-Being total score of healthy controls; CI, confidence interval; OR, odds ratio defined by bivariate logistic regression.

Discussion
==========

The results of our nationwide study showed that up to 25% of adult coeliac disease patients suffer from persistent gastrointestinal symptoms despite a strict gluten-free diet. These findings show an excess of gastrointestinal complaints in treated coeliac patients, although to a somewhat lesser extent than noted in some previous studies \[[@B23],[@B24]\]. Yet it needs to be remembered that comparison between studies is difficult because both the methods to measure and definitions used for persistent symptoms may differ. Further, it is important to distinguish primary non-responsive patients from those investigated in the present study; common reasons for non-responsive coeliac disease are inadvertent gluten intake, refractory coeliac disease and concomitant diseases such as malignancies, microscopic colitis and pancreatic insufficiency \[[@B5],[@B25],[@B26]\]. Patients with any such concomitant condition or refractory coeliac disease were excluded from the present study. Furthermore, although no histological evaluation was undertaken here, judging from both dietary interview and serological testing the majority of participants were adhering strictly to the diet. It would thus seem unlikely that inadvertent gluten intake or presence of the aforesaid adjunct disease would explain the ongoing gastrointestinal symptoms.

In the present study, coeliac patients diagnosed at working age had more current symptoms than those diagnosed at an either younger or older age. Although we cannot confirm the reason for this age dependency of the symptoms, it is possible that changes in established dietary habits are more difficult to cope with simultaneously with other challenges encountered in daily work and family life. Likewise, for some unexplained reason, irritable bowel syndrome (IBS) often emerges in early adulthood \[[@B27]\]. Interestingly, also severe and long-lasting symptoms prior to diagnosis predispose coeliac patients to persistent symptoms. It has been suggested that such long-lasting abdominal complaints result in a chronic cycle of pain in consequence of changes in the gut-brain axis \[[@B28],[@B29]\]. Of note, similar chronic alterations have been hypothesized to be involved in the pathogenesis of IBS, which often co-exists with coeliac disease \[[@B30]-[@B32]\]. There is also evidence suggesting that the symptoms in IBS might be caused by continuous low-grade small-bowel mucosal inflammation \[[@B30],[@B31],[@B33]\], a condition which may persist in coeliac disease despite a strict gluten-free diet \[[@B34],[@B35]\]. Finally, small-intestinal bacterial overgrowth may account for symptoms in both coeliac disease and IBS and is also accompanied by mucosal inflammation \[[@B33],[@B36],[@B37]\]. Whatever mechanisms lie behind the persistent symptoms, our results indicate that they could be ameliorated by diagnosing coeliac disease as early as possible.

The results obtained showed the presence of a coeliac disease-related co-morbidity, another gastrointestinal disorder or non-coeliac food intolerance to predispose to persistent symptoms. It is possible that concomitant gastrointestinal co-morbidity further reinforces the impact of the aforementioned long-lasting changes in the gut-brain axis. Interestingly, a particular association was seen between persistent symptoms and concomitant thyroid disease, which when untreated is known to may cause abdominal complaints, these usually recovering on treatment \[[@B38]\]. However, some patients evince persistent clinical symptoms and reduced health-related quality of life even while on treatment and euthyroid \[[@B39]\]. The pathogenic mechanisms underlying this remain unclear, but clearly the possible connection between thyroid disease and persistent gastrointestinal symptoms in coeliac disease calls for further investigation.

As was the case with gastrointestinal symptoms, a substantial proportion of the coeliac patients here showed reduced health-related quality of life while on a gluten-free diet. Again, long duration of symptoms before diagnosis was a predisposing factor. In contrast, there was no association between clinical manifestations of coeliac disease at diagnosis and current quality of life. This is in line with our previous results showing similar health-related quality of life in screen-detected and symptom-detected coeliac patients on a gluten-free diet \[[@B12],[@B13]\]. These findings constitute further evidence that early detection and dietary treatment of coeliac disease is beneficial even in screen-detected patients with mild or atypical symptoms at diagnosis.

There was a significant association between reduced quality of life and the presence of psychiatric co-morbidities in our study patients. This is in accord with some previous findings and there is also evidence that such coeliac patients might benefit from intensified psychological counseling \[[@B8],[@B18],[@B40]-[@B42]\]. Consequently, health-care professionals should pay particular attention to this patient group, who may need special support with their dietary treatment \[[@B42]\]. Since in the present study 78% of participants with a psychiatric disorder suffered from depression, the role of other psychiatric disorders needs further investigation. Although not statistically significant, there was a trend suggesting that the presence of certain other co-morbidities, for example neurological disorders, other gastrointestinal diseases or non-coeliac food intolerance are factors predisposing to reduced quality of life in coeliac disease. Further studies are warranted to clarify the significance of these issues.

A major strength of our study was a large study cohort with well-defined coeliac disease diagnoses and clinical data. In addition, there were a substantial number of screen-detected patients and subjects with extraintestinal presentation of coeliac disease. A possible limitation, on the other hand, was that a substantial proportion of the participants were recruited through local or national coeliac disease associations, which might have caused some selection bias. Furthermore, our participants showed excellent adherence to the gluten-free diet, this however being in accord with our earlier findings \[[@B12]\]. Although good adherence is beneficial for the patient, in this study it might have concealed the association between poor adherence and reduced quality of life. As a consequence, results may be different in countries where adherence to a gluten-free diet is lower. Although the threshold value of 1 SD to define increased symptoms and reduced quality of life has also been used in other studies, it is somewhat artificial. The fact that healthy controls were not precisely matched with the study participants was also a limitation.

The majority of participants used oats as a regular part of their diet, and this was not associated with increased gastrointestinal symptoms or reduced quality of life. This is important, since the use of oat-containing products in coeliac disease has hitherto remained controversial \[[@B43]\]. Based on our previous results \[[@B44]\] and the findings here, purified oats could be a regular part of a gluten-free diet. One important issue which should be considered in evaluating gastrointestinal symptoms in coeliac patients is that commercial gluten-free products may have marked qualitative differences, for example in the use of additives and preservatives and the amount of fibre \[[@B45]\].

Conclusions
===========

As a conclusion, we showed that many coeliac disease patients suffer from persistent gastrointestinal symptoms and reduced quality of life despite strict dietary treatment. In particular, long-lasting and severe symptoms before the diagnosis and concomitant thyroid, gastrointestinal and psychiatric co-morbidities were significant risk factors for these ongoing health concerns. The results emphasize the importance of early diagnosis and careful follow-up in coeliac disease.
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